FGFR2
Chr 10ADfibroblast growth factor receptor 2
Also known as: BBDS, BEK, BFR-1, CD332, CEK3, CFD1, ECT1, JWS
The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform. Mutations in this gene are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. Multiple alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Jan 2009]
Primary Disease Associations & Inheritance
Definitive — sufficient evidence for diagnostic panels
6 total gene-disease associations curated
Population Genetics & Constraint
gnomAD v4 — loss-of-function & missense intolerance
Highly LoF-intolerant (top ~10% of genes)
Moderately missense-constrained (top ~2.5%)
ClinVar Variant Classifications
478 submitted variants in ClinVar
Classification Summary
Curated Variants Distribution
Classified variants from ClinVar · 5 ACMG categories
| Classification | LoF | Missense + Inframe | Non-coding | Synonymous | Total |
|---|---|---|---|---|---|
Pathogenic | 4 | 12 | 14 | 0 | 30 |
Likely Pathogenic | 1 | 14 | 5 | 0 | 20 |
VUS | 3 | 196 | 33 | 11 | 243 |
Likely Benign | 0 | 6 | 57 | 79 | 142 |
Benign | 0 | 0 | 21 | 0 | 21 |
Conflicting | — | 22 | |||
| Total | 8 | 228 | 130 | 90 | 478 |
LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly
View in ClinVar →Protein Context — Lollipop Plot
FGFR2 · protein map & ClinVar variants
Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.
Gene2Phenotype Curations
FGFR2-related lacrimo-auriculo-dento-digital syndrome (LADD)
definitiveFGFR2-related Beare-Stevenson cutis gyrata syndrome
definitiveFGFR2-related Jackson-Weiss syndrome
definitiveFGFR2-related Antley-Bixler syndrome
strongFGFR2-related Crouzon syndrome
definitiveFGFR2-related Apert Syndrome
definitiveFGFR2-related Pfeiffer syndrome
definitiveGene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org
OMIM — Genotype-Phenotype Relationships
1 OMIM entry
?Scaphocephaly, maxillary retrusion, and impaired intellectual development
MIM #609579Molecular basis of disorder known
Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis
MIM #207410Molecular basis of disorder known
Craniosynostosis, nonspecific
Molecular basis of disorder known
Scaphocephaly and Axenfeld-Rieger anomaly
Molecular basis of disorder known
External Resources
Links to major genomics databases and tools
Variant Interpretation
Population Databases
Gene Resources
Expert Curation
Clinical Trials
Active and recruiting trials from ClinicalTrials.gov
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
RECRUITINGPreliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer
RECRUITINGA Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
RECRUITINGA Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
RECRUITINGMarker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia
RECRUITINGA Phase 2 Clinical Study of ABSK061 and ABSK043
RECRUITINGTesting Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
ACTIVE NOT RECRUITINGA Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
ACTIVE NOT RECRUITINGEfficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma
NOT YET RECRUITINGA Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
RECRUITINGBiomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas: a Pilot Study
RECRUITINGA Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
NOT YET RECRUITINGExternal Resources
Links to major genomics databases and tools